Improvement of the oral praziquantel anthelmintic effect by cyclodextrin complexation

Autor(es)

de Jesus, Marcelo Bispo ^[1] ; Alves Pinto, Luciana de Matos ^[2] ; Fraceto, Leonardo Fernandes ^{[1, 3]} ; Magalhaes, Luiz Augusto ^[4] ; Zanotti-Magalhaes, Eliana Maria ^[4] ; de Paula, Eneida ^[1]

Afiliação do(s) autor(es)

^[1] State Univ Campinas UNICAMP, Inst Biol, Dept Biochem, BR-13083970 Campinas, SP - Brazil

^[2] Univ Fed Lavras, Dept Chem, Lavras, MG - Brazil

^[3] Sao Paulo State Univ, Dept Environm Engn, Sorocaba, SP - Brazil

^[4] Univ Estadual Campinas, Dept Parasitol, Inst Biol, Campinas, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Journal of Drug Targeting; v. 18, n. 1, p. 21-26, JAN 2010.
• Citações Web of Science: 6

Resumo

Schistosomiasis is a parasitic disease which kills a half million people per year, a I I over the world. Praziquantel (PZQ) is the drug-of-choice for schistosomiasis because of its effectiveness, ease of administration, and low cost. However, poor solubility restricts its delivery, especially via the oral route. In this study, we describe beta-cyclodextrin (beta-CD) complexation as an alternative to improve the PZQ bioavailability. Physicochemical analysis were performed to characterize the inclusion complex formed between PZQ and beta-CD. Differential scanning calorimetry (DSC) thermograms and morphological analysis using scanning electronic microscopy (SEM) gave evidences of the complex formation. Diffusion NMR experiments allowed determination of the fraction of PZQ bound to beta-CD (37%) and the association constant (941 +/- 47 M(-1)). The in vivo evaluation of the complexation on the effect of PZQ was performed on mice infected with Schistosoma mansoni (BH strain); after 15 days of treatment with the PZQ:beta-CD complex the efficacy, evaluated by the number of remaining alive worms, was 99%, against 59% elicited by plain PZQ. (AU)

• Processo FAPESP: 02/04103-4 - Avaliacao in vitro e in vivo de praziquantel em sistemas de ciclodextrina.
• Beneficiário: Marcelo Bispo de Jesus
• Linha de fomento: Bolsas no Brasil - Iniciação Científica
• Processo FAPESP: 06/03838-1 - Utilização de ferramentas nanotecnológicas para a indução de morte em células de câncer de próstata
• Beneficiário: Marcelo Bispo de Jesus
• Linha de fomento: Bolsas no Brasil - Doutorado